{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T08:54:25Z","timestamp":1770713665415,"version":"3.49.0"},"reference-count":18,"publisher":"The Journal of Rheumatology","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2024,3,19]]},"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Information on the persistence of tofacitinib (TOF) in psoriatic arthritis (PsA) is scarce in real-world conditions. Our objective was to analyze the persistence and safety of TOF under these conditions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a single-center retrospective longitudinal observational study of all patients with PsA who received at least 1 dose of TOF. The main focus was on adverse events (AEs) and drug survival. Drug survival was analyzed by Kaplan-Meier curves and persistence explanatory factors by multivariate Cox regression models. The hazard ratio (HR) was used to measure association.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Seventy-two patients were included, 54 women and 18 men, mean age 51.9 (SD 11.1) years, mean disease duration of 10.4 (SD 6.99) years. TOF was \u2265 third line of therapy in &gt; 70% of cases. The median survival was 13.0 (IQR 5.3-29.0) months. One-year retention rate was 52.7% (95% CI 42.4-65.6). TOF survival was not influenced by sex, disease duration, comorbidities, or line of treatment. Younger patients (HR 0.96,<jats:italic>P<\/jats:italic>= 0.01) and those with enthesitis (HR 0.37,<jats:italic>P<\/jats:italic>= 0.03) showed lower odds of drug discontinuation. The overall rate of AEs was 52.9 (95% CI 38.5-70.6)\/100 person-years. Most AEs occurred during the first 6 months of exposure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In this real-world study, TOF showed a reasonably good retention rate in a PsA population that was mostly refractory to biologic and oral targeted synthetic disease-modifying antirheumatic drugs. There were no new causes for concern regarding safety. Patients with refractory PsA and enthesitis might be a specific target population for this drug.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.2024-0016","type":"journal-article","created":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T12:20:15Z","timestamp":1711974015000},"page":"682-686","source":"Crossref","is-referenced-by-count":7,"title":["Patients With Psoriatic Arthritis\u2013Related Enthesitis and Persistence on Tofacitinib Under Real-World Conditions"],"prefix":"10.3899","volume":"51","author":[{"given":"Ignacio","family":"Bra\u00f1a","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Loredo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Estefan\u00eda","family":"Pardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Burger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Fern\u00e1ndez-Bret\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8418-7145","authenticated-orcid":false,"given":"Rub\u00e9n","family":"Queiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2024,4,1]]},"reference":[{"key":"2024070105201318000_51.7.682.1","doi-asserted-by":"crossref","first-page":"e0234556","DOI":"10.1371\/journal.pone.0234556","article-title":"Higher prevalence of psoriatic arthritis in the adult population in Spain? A population-based cross-sectional study","volume":"15","author":"Romero P\u00e9rez","year":"2020","journal-title":"PLOS One"},{"key":"2024070105201318000_51.7.682.2","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2024070105201318000_51.7.682.3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217159"},{"key":"2024070105201318000_51.7.682.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615975"},{"key":"2024070105201318000_51.7.682.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615977"},{"key":"2024070105201318000_51.7.682.6","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.201204"},{"key":"2024070105201318000_51.7.682.7","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40744-022-00514-0","article-title":"Sequencing of biologic and target synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: are we ready to redefine the treatment strategy? A perspective","volume":"10","author":"Lubrano","year":"2023","journal-title":"Rheumatol Ther"},{"key":"2024070105201318000_51.7.682.8","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1080\/1744666X.2023.2249235","article-title":"Managing psoriatic arthritis in different clinical scenarios","volume":"19","author":"Queiro","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"key":"2024070105201318000_51.7.682.9","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/acr.23333","article-title":"Impact of comorbidities on tumor necrosis factor inhibitor therapy in psoriatic arthritis: a population-based cohort study","volume":"70","author":"Ballegaard","year":"2018","journal-title":"Arthritis Care Res"},{"key":"2024070105201318000_51.7.682.10","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.151042"},{"key":"2024070105201318000_51.7.682.11","doi-asserted-by":"crossref","first-page":"679009","DOI":"10.3389\/fmed.2021.679009","article-title":"Multicenter study of secukinumab survival and safety in spondyloarthritis and psoriatic arthritis: secukinumab in Cantabria and ASTURias study","volume":"8","author":"Alonso","year":"2021","journal-title":"Front Med"},{"key":"2024070105201318000_51.7.682.12","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3390\/jcm12020467","article-title":"Treatment retention and safety of ixekizumab in psoriatic arthritis: a real life single-center experience","volume":"12","author":"Bra\u00f1a","year":"2023","journal-title":"J Clin Med"},{"key":"2024070105201318000_51.7.682.13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/msc.1684","article-title":"Long-term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis","volume":"21","author":"Pombo-Su\u00e1rez","year":"2023","journal-title":"Musculoskelet Care"},{"key":"2024070105201318000_51.7.682.14","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s40744-023-00584-8","article-title":"Persistence and use of ixekizumab in patients with psoriatic arthritis in real-world practice in Spain. The PRO-STIP study","volume":"10","author":"Joven","year":"2023","journal-title":"Rheumatol Ther"},{"key":"2024070105201318000_51.7.682.15","doi-asserted-by":"crossref","first-page":"5415","DOI":"10.1007\/s12325-023-02693-w","article-title":"Real-world persistence and treatment patterns in patients with psoriatic arthritis treated with anti-IL17 therapy in Spain: the PerfIL-17 study","volume":"40","author":"Joven","year":"2023","journal-title":"Adv Ther"},{"key":"2024070105201318000_51.7.682.16","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223650"},{"key":"2024070105201318000_51.7.682.17","doi-asserted-by":"crossref","first-page":"151979","DOI":"10.1016\/j.semarthrit.2022.151979","article-title":"Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis \u2013 A nationwide cohort study from the DANBIO and DERMBIO registries","volume":"53","author":"Egeberg","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"2024070105201318000_51.7.682.18","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13075-023-03108-5","article-title":"Efficacy of tofacitinib on enthesitis in patients with active psoriatic arthritis: analysis of pooled data from two phase 3 studies","volume":"25","author":"Mease","year":"2023","journal-title":"Arthritis Res Ther"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2024-0016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T12:21:48Z","timestamp":1719836508000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2024-0016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,1]]},"references-count":18,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7,1]]},"published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.3899\/jrheum.2024-0016"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2024-0016","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,1]]}}}